Evidenced in 2 piglet trials with 270 weaned pigs in the Philippines and 32 castrated male weaned pigs in an ETEC F4/F18 challenge trial where location was not stated. In the Philippines, diarrhea incidence decreased from 11.1% to 6.7% and mortality from 7.5% to 1.3% with Globigen Jump Start; in the ETEC trial, the GJS group maintained fecal consistency scores indicating soft to normal feces, ≤1, while the DPP and challenged groups experienced several days of diarrhea.

Evidenced in 4 trials totaling 270 pigs in the Philippines, 200 piglets in Spain across two trials, 314 piglets in France, and >150 piglets in Spain. GJS increased total weight gain by 3.0 to 4.5 kg in the Philippines, increased ADG by >15% across the two Spanish trials, improved ADG by 5% vs spray-dried plasma in France, and achieved significantly higher starter-phase daily gain than ZnO in Spain, with final weight 800 g higher than the ZnO group.

Evidenced in 3 quantified trials with 270 weaned pigs in the Philippines, 32 ETEC-challenged weaned pigs, and 360 weaned pigs in a USA nursery research facility. In the Philippines, FCR improved from 1.96 to 1.64 at 1 kg/t and to 1.47 at 2 kg/t; in the ETEC model, GJS improved feed efficiency during days 6-12 to 0.80 kg gain/kg feed vs 0.39 in challenged controls and 0.45 with DPP; in the USA plasma-replacement trial, FCR was statistically similar but numerically better with GJS at weeks 1, 2, and 6.

Evidenced in 1 blind commercial-farm trial in Spain with >150 weaned piglets allocated to negative control, ZnO, or GJS groups. GJS at 2 kg/t in prestarter produced a final weight of 16.97 kg vs 16.18 kg with ZnO and 16.79 kg in the negative control, significantly higher starter-phase daily gain (0.352 kg vs 0.305 kg with ZnO; p = 0.0194), and lower mortality than control (1.82% vs 3.92%).

Evidenced in 2 trials with 270 weaned pigs in the Philippines and 615 pigs at Iowa State University, USA. In the Philippines, the 2 kg/t GJS group achieved an ROI of 4:1 alongside lower diarrhea, lower mortality, higher weight gain, and improved FCR; in the Iowa trial, GJS had the lowest cost of gain at $0.59/kg, compared with $0.61/kg for control and $0.65/kg for SDPP, while maintaining performance and medical-treatment outcomes comparable to plasma.

Evidenced in 1 field trial in Japan involving 16 sows (2 groups of 8 animals) receiving Globigen Sow at 10 g/sow/day during the 10 days before and 7 days after farrowing. Compared with controls, Globigen Sow reduced fecal shedding of total E. coli, E. coli O141, and Clostridium perfringens, with post-farrowing counts decreasing from 6.75 to 6.30 log10 CFU/g for total E. coli, from 6.41 to 5.60 log10 CFU/g for E. coli O141, and from 4.73 to 4.24 log10 CFU/g for C. perfringens. The study concluded that lowering sow pathogen shedding reduced environmental pathogenic pressure for newborn piglets in the farrowing unit